salemyousefmohamed/IMP3-and-cyclin-D1-

Background: Colorectal cancer (CRC) is the third most frequently diagnosed cancer and the fourth top cause of cancer death worldwide. In Egypt, colorectal carcinoma is considered the 7th common cancer, representing 3.47% of male cancers and 3% of female malignancies. A localized CRC can be entirely cured by surgical resection. Metastasis remains the leading cause of cancer mortality. IMP3 is an independent prognostic biomarker that expects metastasis and poor prognosis in the CRC. The upregulation of nuclear cyclin D1 (CCND1) plays an essential role in pathogenesis and metastases of CRC. Objective: We aimed to investigate the expression of IMP3 and Cyclin D1 in colorectal carcinoma and their correlation with other clinicopathological features. Participants: 80 formalin-fixed and paraffin-embedded blocks of CRC were obtained from patients who underwent surgical resection. The immunohistochemical expression of IMP3 and Cyclin D1 examined and correlated with clinical-pathological parameters and outcome of the patients. Key Results; overexpression of IMP3 and cyclin D1 was noted in (68.75%) and at (56.25%), respectively. IMP3 expression was significantly correlated with tumor grade (P <0.001), TNM stage (P .040), LVI (p 0.005), cyclin D1 was significantly associated with TNM stage (P<0.001), LN metastasis (P<0.001), DM (P0.004).Conclusions: IMP3 and cyclin d1 were associated with poor prognosis in CRC, and so, they comprise an attractive target for anticancer drug development.